Urogen Pharma Ltd (URGN) Stock AnalysisURGNUrogen Pharma Ltd

UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Urogen Pharma Ltd is currently not a strong buy due to its low RSI of 19.34, indicating it is oversold, but it has a significant upside potential with analyst price targets ranging from $50 to $75. The stock has experienced a recent decline of 11.04% over the past five days, which may present a buying opportunity if the price stabilizes. However, the risk remains with a forward P/E of 36.50, suggesting that the stock may be overvalued compared to its earnings potential.

4 analysts cover URGN: 3 rate it Buy, 1 Hold and 0 Sell. The average price target is 40.25.